Learning From Influenza Vaccine Errors to Prepare for COVID-19 Vaccination Campaigns

It is evident that many underlying causes of flu vaccine–related errors could just as easily lead to errors associated with the new COVID-19 vaccines and the hundreds of millions of doses that will be given. It will be crucial for any healthcare provider who plans to stock and/or administer COVID-19 vaccines to learn from these prior vaccine-related errors, anticipate that similar errors could happen with the COVID-19 vaccines, and take the necessary steps to prepare their facilities and healthcare teams to mitigate the risk of vaccine-related errors.

Read More »

Designing Successful Medication Reconciliation Programs

When deciding on where to place med rec resources, start by looking at where most of your admissions come from. For many hospitals, admissions largely come from planned surgical procedures or the Emergency Department, so these are prime areas in which to consider having a med rec team collect medication histories.

Read More »

Drug Diversion Regulatory Requirements and Best Practices

To support the diversion program effort, refer to the controlled substance- and diversion-related requirements with which facilities must comply. Sources of such requirements include the Centers for Medicare & Medicaid Services (CMS), DEA, the Food and Drug Administration (FDA), the Environmental Protection Agency (EPA), survey agencies, state regulations, and professional boards.

Read More »

During the Pandemic, Aspire to Identify and Prevent Medication Errors and to Avoid Blaming Attitudes

Occasionally, a “resource” nurse is available to assist in the ICU. However, too often, the resource nurse is tasked with auditing activities to ensure proper nursing documentation rather than assisting with clinical patient care. Subsequently, nurses have been reprimanded for documentation failures and urged to document care they were unable to provide.

Read More »

Q&A: Many Hospitals Still Don’t Have Drug Diversion Programs

The Porter Research survey commissioned by Invistics found that nine out of 10 surveyed believe their facility’s drug diversion program is the same or even better than other organizations, and two out of three are confident or very confident that their drug diversion program successfully identifies employees who divert drugs. But there is definitely a disconnect, because 70% of participants said they believe most diversion incidents in the U.S. go undetected.

Read More »

NIOSH Seeks Comment on Updated List of Hazardous Drugs in Healthcare

The proposal includes a name change and reorganization of drug lists so that not all antineoplastic drugs, most often associated with cancer treatments, are grouped together. Formerly the “NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings,” the list will be called more simply the “NIOSH List of Hazardous Drugs in Healthcare Settings, 2020.”

Read More »